Talk:Sandoz

message: Research on LSD peaked in the 1950s and early 1960s.
:This is not true.  It is more accurate to say that research became more difficult after drug prohibition. --Viriditas  | Talk 18:56, 30 Jan 2005 (UTC)
thread_title: LSD

message: :Image:Sandozlogo.jpg is being used on this article. I notice the image page specifies that the image is being used under fair use but there is no explanation or rationale as to why its use in this Wikipedia article constitutes fair use. In addition to the boilerplate fair use template, you must also write out on the image description page a specific explanation or rationale for why using this image in each article is consistent with fair use.
Please go to the image description page and edit it to include a fair use rationale. Using one of the templates at Wikipedia:Fair use rationale guideline is an easy way to insure that your image is in compliance with Wikipedia policy, but remember that you must complete the template. Do not simply insert a blank template on an image page.
If there is other other fair use media, consider checking that you have specified the fair use rationale on the other images used on this page.  Note that any fair use images uploaded after 4 May, 2006, and lacking such an explanation will be deleted one week after they have been uploaded, as described on criteria for speedy deletion. If you have any questions please ask them at the Media copyright questions page. Thank you.BetacommandBot 22:24, 5 June 2007 (UTC)
thread_title: Fair use rationale for Image:Sandozlogo.jpg

message: I work at Sandoz. As part of the Sandoz Communications team, I would like to make the following suggestions. All of my suggestions are fact-based and supported by official company documents and published information. 
Type: Subsidiary
:Sandoz is a Division of Novartis. "Subsidiary" implies a separate legal entity.
Founded: 2003, when Novartis united its generics business under the global Sandoz brand.
Key People: Jeff George, CEO
:Jeff George is "Head of Sandoz". The title of "CEO" is held by Joseph Jimenez, CEO of Novartis. 
Products --> recommend changing to "Top Products". 
:Argumentation: Sandoz has over 1000 molecules in its portfolio, so it is inaccurate to arbitrarily select some products and not others. Each year, Sandoz discloses its top ten product list in the 20-F filing.
Top Products: 
* enoxaperin
* amoxicillin/clavulanic acid
* omeprazole
* tacrolimus
* losartan
* fentanyl
* lansoprazole
* simvastatin
* acetylcystein
* amlodipine/benayepril
:Argumentation: as above. Each year, Sandoz discloses its top ten product list in the 20-F filing, so this list would be most accurate, balanced and representative. This suggested list of products reflects the 2010 list.
Revenue: USD 8.5 Billion (2010)
:Argumentation: As published in the Novartis 2010 Annual Report (p.45). 
Employees: 23,536 (as of December 31, 2010)
:Argumentation: As published in the Novartis 2010 Annual Report (p.45).
Globalcommunications (talk) 16:52, 9 March 2011 (UTC)
thread_title:  Suggestions for edits to sidebar 

message: I work at Sandoz. As part of the Sandoz Communications team, I would like to make the following suggestions. All of my suggestions are fact-based and supported by official company documents and published information.
Revenue:
* 2011 - US$9.5 billion (Novartis 2011 Annual Report, p.40)
Employees: 
* 24,000 (US SEC Form 20-F 2011, p. 62)
Presence:
* 140 countries (Sandoz corporate website)
Globalcommunications (talk) 15:11, 27 July 2012 (UTC)
thread_title:  Additional suggestions from Sandoz Global Communications 

message: I merged this stub of an article, with almost no citations, in Novartis today Jytdog (talk) 21:58, 19 October 2013 (UTC)
thread_title:  merge